RxDoctor Payments Data

Jorge Grillasca Palou, MD

Nephrology · Coto Laurel, PRNPI 1467493726

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 58.4% of the total. Reporting peaked in 2019 at $2,497 and has fallen 85.0% since, to $376 in 2025.

$4,062in general payments, 2019–2025

Across 29 payments — averaging $140.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$351
  • Fresenius USA Marketing, Inc.$292
  • Nxstage Medical, Inc.$247
  • Amgen$236
  • Bayer$224
  • plus $341 from 5 others

What the payments were for

  • Consulting fees$2,04050%
  • Travel & lodging$2105%
  • Food & beverage$1,71342%
  • Education$992%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,062 in reported general payments places this provider in the 80th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$34,694
Medicare patients
48
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol305$196,894
JardianceEmpagliflozin138$88,869
Sevelamer Carbonate564$67,126
LokelmaSodium Zirconium Cyclosilicate83$65,955
KerendiaFinerenone90$60,288
Calcium Acetate132$14,590
JanuviaSitagliptin Phosphate13$9,527
Calcitriol383$7,777
LantusInsulin Glargine,hum.Rec.Anlog49$4,122
Losartan Potassium506$3,960
Nifedipine ErNifedipine69$2,226
HumalogInsulin Lispro23$1,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,443
NovologInsulin Aspart18$1,423
Irbesartan70$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$351$262,849388 claims
Boehringer IngelheimJardiance$75$88,869138 claims
BayerKerendia$224$60,28890 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Coto Laurel

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →